Faculty & Staff

Alexandra L. Hanlon, PhD
Associate Professor

As an Associate Professor, Dr. Hanlon teaches graduate Biostatistics and SAS Programming; she specializes in the facilitation of research by providing statistical support to researching faculty members and graduate students. Dr. Hanlon actively serves on scientific editorial boards and frequently makes presentations at conferences of professional associations to share on-going research and recent findings. She trains researchers in relevant statistical methodologies to enhance their research efforts; she is an active grant-writer and plays a prominent role in institutional grants; she facilitates promulgation of research findings by co-authoring scores of publications that disseminate research findings, assuming responsibility for the statistical evidence and analyses in these publications. Dr. Hanlon has a wealth of collaborative experience in cancer research, with her doctoral research topic in hierarchical mixed effects modeling of PSA levels in men treated with radiation therapy for prostate cancer. She has recently been involved in pharmaceutical drug development research and approval. Dr. Hanlon’s breadth of experience in academia and industry provide her with insight relevant to perspectives unique to educators, clinicians, patients, and society.

Dr. Hanlon is also the Director of the Biostatistics Research Support Center (BRSC). The BRSC offers comprehensive statistical consultation and computational services to faculty, staff, and students in the College of Health Professions and throughout Temple University. BRSC personnel are available for discussion at all stages of research, including preparation of grants and contracts, assistance in analyzing and presenting research data, and statistical review of manuscripts in the publication process. 

Education:

Temple University, Ph.D. in Statistics
University of California, Irvine, MS in Mathematical Statistics

Recent Publications:

Feng M, Hanlon AL, Pisansky TM, Kuban D, Catton CN, Michalski JM, Zelefsky MJ, Kupelian PA, Pollack A, Kestin LL, Valicenti RK, Deweese TL, Sandler HM.  Predictive Factors for Late Genitourinary and Gastrointestinal Toxicity in Patients With Prostate Cancer Treated With Adjuvant or Salvage Radiotherapy. International Journal of Radiation Oncology, Biology and Physics:  April 6, 2007 (Epub ahead of print).

Eade TN, Hanlon AL, Horwitz EM, Buyyounouski MK, Hanks GE, Pollack A.  What dose of external-beam radiation is high enough for prostate cancer?  Int J Radiat Oncol Biol Phys:  Mar 28, 2007 (Epub ahead of print).

Bass SB, Ruzek SB, Gordon TF, Hanlon AL.  Preparedness for a smallpox outbreak: comparing metrics for assessing levels of vaccination among health-care workers by state.  Epidemiol Infect 135, 622-33, 2007.

Morgan PB, Hanlon AL, Horwitz EM, Buyyounouski MK, Uzzo RG, Pollack A..  Radiation dose and late failures in prostate cancer.  Int J Radiat Oncol Biol Phys 67,1074-81, 2007.

D’Ambrosio DJ, Hanlon AL, Al-Saleem T, Feigenberg SJ, Horwitz EM, Uzzo RG, Pollack A, Buyyounouski MK.  The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 67, 1082-7, 2007.

Feigenberg SJ, Hanlon AL, Langer C, Goldberg M, Nicolaou N, Millenson M, Coia LR, Lanciano R, Movsas B.  A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer.  J Thorac Oncol 2, 287-92, 2007.

Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg D.  A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer. Am J Clin Oncol 29, 458-62, 2006.

Konski A, Watkins-Bruner D, Feigenberg S, Hanlon AL, Kulkami S, Beck JR, Horwitz EM, Pollack A.  Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer.  Int J Radiat Oncol Biol Phys 66(2): 408-15, 2006.

Konski A, Eisenberg D, Horwitz E, Hanlon AL, Pollack A, Hanks GE.  Does age matter in the selection of treatment for men with early-stage prostate cancer?  Cancer 106(12): 2598-602, 2006.

Freedman GM, Anderson PR, Eisenberg DF, Hanlon AL, Wang L, Nicolaou N.  Intensity modulated radiation therapy (IMRT) decreases acute skin toxicity for women receiving radiation for breast cancer.  Am J Clin Oncol 29(1): 66-70, 2006.

Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG.  The natural history of observed enhancing renal masses:  meta-analysis and review of the world literature.  Journal of Urology 175(2):  425-431, 2006.

Berger AC, Sigurdson ER, LeVoyer T, Hanlon AL, Mayer RJ, MacDonald JS, Catalano PJ, Haller DG.  Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes.  J Clin Oncol 23(34): 8706-12, 2006.

Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Konski AA, Movsas B, Greenberg RE, Uzzo RG, Ma CM, McNeeley SW, Buyyounouski MK, Price RA Jr.  Dosimetry and preliminary acute toxicity in the first 100 mean treated for prostate cancer on a randomized hypofractionation dose escalation trial.  International Journal of Radiation Oncology, Biology and Physics 64(2):  518-526, 2006.

Siegelmann-Danieli N, Ben-Izhack O, Hanlon AL, Ridge JA, Stein ME, Khandelwal V, Langer CJ (2005).  P53 alteration in oral tongue cancer is not significantly associated with age at diagnosis or tobacco exposure.  Tumori 91(4) 346-50.

Diratzouian H, Freedman GM, Hanlon AL, Eisenberg DF, Anderson PR.  Importance of physical examination in the absence of a mammographic abnormality for the detection of early-stage breast cancer.  Clin Breast Cancer 6(4):  330-333, 2005.

Buyyounouski MK, Hanlon AL, Eisenberg DF, Horwitz EM, Feigenberg SJ, Uzzo RG, Pollack A.  Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer.  International Journal of Radiation Oncology, Biology and Physics 63(5): 1455-1462, 2005.

Andrews SF, Horwitz EM, Feigenberg SJ, Eisenberg DF, Hanlon AL, Uzzo RG, Pollack A.  Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?  Cancer 104(2):  299-304, 2005.

Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg D, Pollack A.  Long-term androgen deprivation increases grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy.  International Journal of Radiation Oncology, Biology and Physics 62(2): 397-405, 2005.

Freedman GM, Anderson PR, Hanlon AL, Eisenberg DF, Nicolaou N.  Pattern of local recurrence after conservative surgery and whole-breast irradiation.  International Journal of Radiation Oncology, Biology and Physics 61: 1328-36, 2005.

Buyyounouski MK, Hanlon AL, Horwitz EM, Uzzo RG, Pollack A.  Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation.  International Journal of Radiation Oncology, Biology and Physics 61: 1291-8, 2005.

Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg DF, Pollack A.  What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?  International Journal of Radiation Oncology, Biology and Physics 61: 1003-1010, 2005.

Goldberg M, Gupta D, Sasson AR, Movsas B, Langer CJ, Hanlon AL, Wang H, Scott WJ.  The surgical management of superior sulcus tumors: a retrospective review with long-term follow-up.  Ann Thorac Surg 79:  1174-9, 2005.

Konski A, Doss M, Milestone B, Haluszka O, Hanlon A, Freedman G, Adler L.  The integration of 18-fluoro-deoxy-glucose position emission tomography and endoscopic ultrasound in the treatment-planning process for esophageal carcinoma.  International Journal of Radiation Oncology, Biology and Physics 61:  1123-1128, 2005.

Jacob R, Hanlon AL, Horwitz EM, Movsas, B, Uzzo RG, Pollack A.  Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement.  International Journal of Radiation Oncology, Biology and Physics 61: 695-701, 2005.

Recent Presentations:

“Evaluating the risk of contralateral neck failure in patients with SCC of the tonsil treated only to the ipsilateral tonsil and neck for N+ disease.”  American Society for Therapeutic Radiology and Oncology, Multidisciplinary Head and Neck Symposium, Rancho Mirage, CA, January 2007.

“Adjusted Radiotherapy Dose Response Curves Following Treatment for Prostate Cancer:  Biochemical Failure and Distant Metastasis.”  American Society for Therapeutic Radiology and Oncology, 48th Annual Meeting, Philadelphia, November 2006.

“Year 4 Evaluation Results of Leadership 101, an After-School Program for Urban, Primarily African-American, Adolescents:  Reducing Risk Among Middle School Students and Keeping Strong High School Students Strong.”  Office of Adolescent Pregnancy Programs Evaluation Conference, Pittsburgh, PA, September 2006.

“Focus on Adolescent/Teen Health Issues: Evaluation of the Leadership 101 Program.”  Invited Speaker for Crozer Keystone Health System Quality Day, Drexel Hill, May 2006.

“Predictors of Hormone Refractory Disease in Men Treated with Salvage Androgen Deprivation Following Definitive Radiotherapy for Prostate Cancer.” American Society for Therapeutic Radiology and Oncology, 47th Annual Meeting, Denver, November 2005.